| DB ID | MyCo_3783 |
| Title | Regional Impact of COVID-19-Associated Pulmonary Aspergillosis (CAPA) during the First Wave |
| Year | 2022 |
| PMID | 35205851 |
| Fungal Diseases involved | Pulmonary aspergillosis |
| Associated Medical Condition | COVID-19 patients |
| Genus | Aspergillus |
| Species | fumigatus |
| Organism | Aspergillus fumigatus |
| Ethical Statement | This study conforms to the principles outlined in the Decla- ration of Helsinki and was approved by the research board of the Amphia Hospital (N2020-0315), each participating institution, and the ethics board of MEC-U, The Netherlands (W20.157). |
| Site of Infection | Lungs |
| Opportunistic invasive | Opportunistic |
| Sample type | Body fluid |
| Sample source | Tracheal aspirates |
| Host Group | Human |
| Host Common name | Human |
| Host Scientific name | Homo sapiens |
| Biomarker Name | GM |
| Biomarker Full Name | Galactomannan |
| Biomarker Type | Diagnostic |
| Biomolecule | Protein |
| Geographical Location | Netherlands |
| Cohort | Here conducted a regional multi-centre, retrospective cohort study over the months March and April 2020. All adult patients with laboratory confirmed COVID-19 admitted to the ICU of the main study centre (Amphia hospital, Breda), with and without mycological arguments for CAPA were assessed. Patients were eligible for inclusion if they were 18 years or older with rt-PCR confirmed SARS-CoV-2 infection (COVID-19) and admitted to the ICU of one of the study centres, with the first day of ICU admission within the study period. |
| Cohort No. | 58 Patients and 68 controls |
| Age Group | > 18 |
| P Value | None |
| Sensitivity | None |
| Specificity | None |
| Positive Predictive Value | None |
| MIC | None |
| Fold Change | None |
| Pathway | None |
| Disease Introduction Mechanism | The pandemic of Coronavirus Disease 2019 (COVID-19), caused by the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), has high attack rates, intensive care unit (ICU) admissions, and mortality. Substantial case fatality rate is reported in patients admitted to the ICU, of which half developed secondary infections. Late February 2020, the province of North-Brabant in the Netherlands emerged as a hotspot for COVID-19. In April 2020, we reported the first remarkable number of cases of invasive pulmonary aspergillosis (IPA) occurring in COVID-19 patients admitted to the ICU, with the first azole resistant Aspergillus fumigatus isolate. Early international warnings and case series also reported on COVID-19-associated pulmonary aspergillosis (CAPA). Dramatic high rates were noted in COVID-19 ICU patients of possible/probable CAPA (19–33%) with high mortality rates (44–66%). |
| Technique | Assay |
| Analysis Method | GM lateral flow assa (LFA) |
| ELISA kits | Platelia™ Aspergillus Ag Kit (BioRad, Hercules, CA, USA) |
| Assay Data | None |
| Validation Techniques used | GM-Platelia™ Aspergillus Ag ELISA, GM lateral flow assay |
| Up Regulation Down Regulation | Positive |
| Sequence Data | None |
| External Link | None |
